Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carla Cristina Lopes has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PIK3CA silencing restores anoikis sensitivity in endothelial cells

    by Diego Mauro Carneiro Pereira, Ana Paula de Sousa Mesquita, Amanda da Silva Cruz, Lucélia Donatti, Helena Bonciani Nader, Carla Cristina Lopes

    Background: The development, differentiation, and homeostasis of adherent cells are regulated by interactions among cells, the extracellular matrix (ECM), and soluble factors. Loss of these contacts induces anoikis, a specific form of apoptosis. Tumor cells acquire resistance to anoikis, enabling them to survive without anchorage, invade the vascular system, and colonize distant organs in a process known as metastasis. Activation of the PI3K/Akt signaling pathway is the most common mechanism underlying the acquisition of anoikis resistance in cancer cells. The role of phosphoinositide 3-kinase (PI3K) in cancer is highlighted by the frequent mutation of the gene encoding the p110α catalytic subunit in the most common human cancers. In this study, we aimed to elucidate the role of PI3K (p110α catalytic subunit) in the acquisition of the anoikis-resistant phenotype and in the regulation of cellular characteristics directly related to tumorigenesis. Methods and results: To this end, we performed PIK3CA gene silencing in anoikis-resistant endothelial cells. Consequently, these cells exhibited a reversal of malignancy-associated traits, including morphological characteristics, anoikis resistance, clonogenic potential, proliferation rate, invasiveness, and adhesive capacity, resembling those of wild-type endothelial cells. Furthermore, we observed an increased rate of apoptosis, accompanied by changes in the expression of pro- and anti-apoptotic molecules, as well as increased caspase activation. Conclusions: In summary, our findings demonstrate that PIK3CA silencing reverses key features of the anoikis-resistant endothelial cell phenotype and provides new insights into the molecular mechanisms underlying anoikis resistance. Graphical Comparative diagram of the main characteristics of anoikis-resistant endothelial cells before and after PIK3CA silencing. Some elements of the graphical abstract were adapted from Servier Medical Art ( https://smart.servier.com/ , accessed 26 August 2025).

  • Open Access

    SDC4 silencing promotes cell cycle arrest at the restriction point (R point) in anoikis-resistant endothelial cells

    by Bianca Zaia Franco Ferreira, Diego Mauro Carneiro Pereira, Jessica Oyie Sousa Onyeisi, Ranyelison Silva Machado, Rodrigo Esaki Tamura, Helena Bonciani Nader, Carla Cristina Lopes

    Many tumor cells exhibit resistance to anoikis, facilitating their invasion and contributing to tumor metastasis. Previous studies have shown that anoikis-resistant endothelial cells overexpress syndecan-4 (SDC4), a co-receptor for growth factors that interacts with extracellular matrix (ECM) proteins. While SDC4 is well-known for its role in cellular processes such as adhesion, migration, and proliferation, its specific involvement in cell cycle dysregulation in tumor cells remains poorly understood. This study aimed to investigate the role of SDC4 in regulating the cell cycle in anoikis-resistant endothelial cells. Methods included the use of wild-type endothelial cells (EC), EJ-ras oncogene-transfected EC (EJ-ras EC), anoikis-resistant EC (Adh1-EC), and SDC4-silenced EC (miR-Syn-4-1-Adh-EC). Gene and protein expression of regulatory molecules across different phases of the cell cycle were analyzed using qPCR, western blotting, and flow cytometry. The Integrated Biomarker Response (IBR) index was employed to interpret cellular responses, and cell viability was assessed after adhesion blockade. Results showed that while cyclin D1 was highly expressed in the G1 phase, SDC4-silenced cells exhibited increased p27 expression, which impairs the activity of the cyclin E-CDK2 complex, suggesting a potential hindrance to cell cycle progression. Additionally, a reduction in cyclin B1 expression was observed. The IBR index for cyclins and CDKs was 2.19 and 3.24, respectively, following SDC4 silencing, compared to 4.72 and 4.41 in anoikis-resistant cells. Furthermore, SDC4 silencing increased the cells’ susceptibility to anoikis. These findings highlight SDC4’s ability to modulate key processes involved in cancer development, emphasizing its potential as a therapeutic target in cancer treatment.

  • Effects of syndecan‐4 silencing on the extracellular matrix remodeling in anoikis‐resistant endothelial cells

    by Jessica Oyie Sousa Onyeisi, Helena Bonciani Nader, Carla Cristina Lopes

    Anoikis is a process of programmed cell death induced by the loss of cell/matrix interactions. In previous work, we have shown that the acquisition of anoikis resistance upregulates syndecan‐4 (SDC4) expression in endothelial cells. In addition, SDC4 gene silencing by microRNA interference reverses the transformed phenotype of anoikis‐resistant endothelial cells. Due to this role of SDC4 in regulating the behavior of anoikis‐resistant endothelial cells, we have evaluated that the functional consequences of SDC4 silencing in the extracellular matrix (ECM) remodeling in anoikis‐resistant rabbit aortic endothelial cells submitted to SDC4 gene silencing (miR‐Syn4‐Adh‐1‐EC). For this, we evaluated the expression of adhesive proteins, ECM receptors, nonreceptor protein‐tyrosine kinases, and ECM‐degrading enzymes and their inhibitors. Altered cell behavior was monitored by adhesion, migration, and tube formation assays. We found that SDC4 silencing led to a decrease in migration and angiogenic capacity of anoikis‐resistant endothelial cells; this was accompanied by an increase in adhesion to fibronectin. Furthermore, after SDC4 silencing, we observed an increase in the expression of fibronectin, collagen IV, and vitronectin, and a decrease in the expression of integrin α5β1 and αvβ3, besides that, silenced cells show an increase in Src and FAK expression. Quantitative polymerase chain reaction and Western blot analysis demonstrated that SDC4 silencing leads to altered gene and protein expression of MMP2, MMP9, and HSPE. Compared with parental cells, SDC4 silenced cells showed a decrease in nitric oxide production and eNOS expression. In conclusion, these data demonstrate that SDC4 plays an important role in ECM remodeling. In addition, our findings represent an important step toward understanding the mechanism by which SDC4 can reverse the transformed phenotype of anoikis‐resistant endothelial cells.


  • Leading Roles of Heparan Sulfate in Angiogenesis and Cancer

    by Carla Cristina Lopes, Jessica Oyie Sousa Onyeisi, Maria Cecilia Zorél Meneghetti, Carina Mucciolo Melo, Carolina Meloni Vicente, Luis Cesar de Azevedo, Maria Aparecida da Silva Pinhal, Leny Toma, Helena Bonciani Nader

  • Open Access

    Nitric oxide regulates adhesiveness, invasiveness, and migration of anoikis-resistant endothelial cells

    by A.P.S. Mesquita, M. Matsuoka, S.A. Lopes, P.C.A. Pernambuco Filho, A.S. Cruz, H.B. Nader, C.C. Lopes

    Anoikis is a type of apoptosis that occurs in response to the loss of adhesion to the extracellular matrix (ECM). Anoikis resistance is a critical mechanism in cancer and contributes to tumor metastasis. Nitric oxide (NO) is frequently upregulated in the tumor area and is considered an important player in cancer metastasis. The aim of this study was to evaluate the effect of NO on adhesiveness, invasiveness, and migration of anoikis-resistant endothelial cells. Here, we report that anoikis-resistant endothelial cells overexpress endothelial nitric oxide synthase. The inhibition of NO release in anoikis-resistant endothelial cells was able to decrease adhesiveness to fibronectin, laminin, and collagen IV. This was accompanied by an increase in cell invasiveness and migration. Furthermore, anoikis-resistant cell lines displayed a decrease in fibronectin and collagen IV protein expression after L-NAME treatment. These alterations in adhesiveness and invasiveness were the consequence of MMP-2 up-regulation observed after NO release inhibition. The decrease in NO levels was able to down-regulate the activating transcription factor 3 (ATF3) protein expression. ATF3 represses MMP-2 gene expression by antagonizing p53-dependent trans-activation of the MMP-2 promoter. We speculate that the increased release of NO by anoikis-resistant endothelial cells acted as a response to restrict the MMP-2 action, interfering in MMP-2 gene expression via ATF3 regulation. The up-regulation of nitric oxide by anoikis-resistant endothelial cells is an important response to restrict tumorigenic behavior. Without this mechanism, invasiveness and migration potential would be even higher, as shown after L-NAME treatment.


  • Open Access

    microRNA‐140‐3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecan‐4

    by Jessica Oyie Sousa Onyeisi, Burkhard Greve, Nancy Adriana Espinoza‐Sánchez, Ludwig Kiesel, Carla Cristina Lopes, Martin Götte

    Syndecan‐4, a predicted target of the microRNA miR‐140‐3p, plays an important role in multiple steps of tumor progression and is the second most abundant heparan sulfate proteoglycan produced by breast carcinoma cell lines. To investigate the potential functional relationship of miR‐140‐3p and syndecan‐4, MDA‐MB‐231, SKBR3, and MCF‐7 breast cancer (BC) cells were transiently transfected with pre‐miR‐140‐3p, syndecan‐4 small interfering RNAJ, or control reagents, respectively. Altered cell behavior was monitored by adhesion, migration, and invasion chamber assays. Moreover, the prognostic value of syndecan‐4 was assessed by Kaplan–Maier Plotter analysis of gene expression data from tumor samples of 4929 patients. High expression of syndecan‐4 was associated with better relapse‐free survival in the whole collective of BC patients, but correlated with a worse survival in the subgroup of estrogen receptor negative and estrogen/progesterone‐receptor negative patients. miR‐140‐3p expression was associated with improved survival irrespective of hormone receptor status. miR‐140‐3p overexpression induced posttranscriptional downregulation of syndecan‐4, as demonstrated by quantitative real‐time PCR (qPCR), flow cytometry, and luciferase assays, resulting in decreased BC cell migration and matrigel invasiveness. Furthermore, miR‐140‐3p overexpression and syndecan‐4 silencing increased the adhesion of BC to fibronectin and laminin. qPCR analysis demonstrated that syndecan‐4 silencing leads to altered gene expression of adhesion‐related molecules, such as fibronectin and focal adhesion kinase, as well as in the gene expression of the proinvasive factors matrix metalloproteinase 2 and heparanase (also known as HPSE). We conclude that syndecan‐4 is a novel target of miR‐140‐3p that regulates BC cell invasiveness and cell‐matrix interactions in the tumor microenvironment.


  • Open Access

    Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer

    by Jessica Oyie Sousa Onyeisi, Carla Cristina Lopes, Martin Götte

    Cancer is an important cause of morbidity and mortality worldwide. Advances in research on the biology of cancer revealed alterations in several key pathways underlying tumorigenesis and provided molecular targets for developing new and improved existing therapies. Syndecan-4, a transmembrane heparan sulfate proteoglycan, is a central mediator of cell adhesion, migration and proliferation. Although several studies have demonstrated important roles of syndecan-4 in cell behavior and its interactions with growth factors, extracellular matrix (ECM) molecules and cytoskeletal signaling proteins, less is known about its role and expression in multiple cancer. The data summarized in this review demonstrate that high expression of syndecan-4 is an unfavorable biomarker for estrogen receptor-negative breast cancer, glioma, liver cancer, melanoma, osteosarcoma, papillary thyroid carcinoma and testicular, kidney and bladder cancer. In contrast, in neuroblastoma and colorectal cancer, syndecan-4 is downregulated. Interestingly, syndecan-4 expression is modulated by anticancer drugs. It is upregulated upon treatment with zoledronate and this effect reduces invasion of breast cancer cells. In our recent work, we demonstrated that the syndecan-4 level was reduced after trastuzumab treatment. Similarly, syndecan-4 levels are also reduced after panitumumab treatment. Together, the data found suggest that syndecan-4 level is crucial for understanding the changes involving in malignant transformation, and also demonstrate that syndecan-4 emerges as an important target for cancer therapy and diagnosis.


  • Heparan sulfate proteoglycans as targets for cancer therapy: a review

    by Jessica Oyie Sousa Onyeisi, Bianca Zaia Franco Ferreira, Helena Bonciani Nader, Carla Cristina Lopes

    Heparan sulfate proteoglycans (HSPGs) play important roles in cancer initiation and progression, by interacting with the signaling pathways that affect proliferation, adhesion, invasion and angiogenesis. These roles suggest the possibility of various strategies of regulation of these molecules. In this review, we demonstrated that the anticancer drugs can regulate the heparan sulfate proteoglycans activity in different ways: some act directly in core protein, and can bind to a specific type of HSPG. Others drugs interact with glycosaminoglycans chains, and others can act directly in enzymes that regulate HSPGs levels. We also demonstrated that the HSPGs drug targets can be divided into four groups: monoclonal antibodies, antitumor antibiotic, natural products, and mimetics peptide. Interestingly, many drugs demonstrated in this review are approved by FDA and is used in cancer therapy (Food and Drug Administration) like trastuzumab, panitumumab, bleomycin and bisphosphonate zoledronic acid (ASCO) or are in clinical trials like codrituzumab and genistein. This review should help researchers to understand the mechanism of action of anticancer drugs existing and also may inspire the discovery of new drugs that regulate the heparan sulfate proteoglycans activity. ABSTRACT


  • Effects of syndecan-4 gene silencing by micro RNA interference in anoikis resistant endothelial cells

    by Jessica Oyie Sousa Onyeisi, Paulo Castanho de Almeida Pernambuco Filho, Ana Paula de Sousa Mesquita, Luis Cesar de Azevedo, Helena Bonciani Nader, Carla Cristina Lopes


  • Interaction of Trastuzumab with biomembrane models at air-water interfaces mimicking cancer cell surfaces

    by Andrei Sakai, Ana Paula de Sousa Mesquita, Erica Valadares de Castro Levatti, Anita Hilda Straus, Helena B. Nader, Carla Cristina Lopes, Luciano Caseli